Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

aceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertaintie
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... Management, Intelligent Traffic Management, Communication, Monitoring), and by ... Forecast to 2019” segments the global market into ... revenues. It also identifies the drivers and restraints ... and challenges. , Browse 75 market tables and ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... 24, 2014 According to new ... Data Center Types (Colocation, Enterprise, Telecom), by Design ... 1, Tier 2, Tier 3, Tier 4) - ... and segments the Data Center Construction Market into ... of revenues. This research report also identifies the ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... ... The global Nanomedicine market continues to register robust growth largely fueled by unique properties ... in funding across the globe, and increased hype around nanotechnology. , ... San Jose, CA (PRWEB) June 25, ...
... will offer expanded access to choice, quality and cost-efficiency ... and AVENTURA, Fla., June 24 Galichia Heart Hospital ... for Galichia to host MSI-coordinated, highly specialized, urologic surgical ... immediately, expands Galichia,s capabilities as a center of excellence ...
... 24 Kewaunee Scientific Corporation (Nasdaq: KEQU ) ... fiscal year ended April 30, 2009. , , ... $1.66 per diluted share, up from net earnings of $3,134,000, ... Earnings benefited from higher sales volume, lower manufacturing costs and ...
Cached Biology Technology:World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM) 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM) 3Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16% 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16% 3Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16% 4Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16% 5
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... the living world compete with members of their ... much they invest into their competitive ability. Some ... access to high-quality resources, while others seem to ... lower-quality resources that are left over for them. ... human societies seems to fluctuate considerably over time. ...
(Date:10/28/2014)... in German . ... acquire sufficient food when times are lean? By studying ... d,Ivoire researchers of the Max Planck Institute for Evolutionary ... how great apes can acquire extra energy needed to ... their sleeping nests more en route to breakfast sites ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3
... In order to reduce the Province,s greenhouse gas emissions, the ... renewable biofuels such as ethanol, from biomass grown in BC. ... other food products continues to raise concerns about impact on ... a source of next generation renewable biofuels. In the ...
... August 23, 2009 Case Western Reserve University School ... Molecular Biology, Jeff Coller, Ph.D., and his team discovered ... altering a common understanding of how gene expression is ... in Saccharomyces cerevisiae ", is published in the ...
... WEST CHESTER, Pa., Aug. 4 ComCam International, Inc. ... control products, solutions and services, today announced that it has ... software and systems integration for a Maritime Domain Awareness and ... CEO Don Gilbreath stated, "Our two companies have worked informally ...
Cached Biology News:New genomic research to tackle supply and demand issues in emerging forestry biofuels industry 2New genomic research to tackle supply and demand issues in emerging forestry biofuels industry 3Case Western Reserve University researcher demonstrates that messenger RNA are lost in translation 2ComCam Selected by ePortation on New Maritime Domain Awareness Project 2
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
Request Info...
... Our entry-level automated perfusion system. For ... perfusion, physiology, biophysics, electrochemistry, or general ... with 10 millisecond accuracy Run ... Microprocessor-based for accuracy and flexibility ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Biology Products: